Novartis AG - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NVS New York 2836 www.novartis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Novartis AG

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 - Jun 8th, 2026 1:00 am
How $350,000 in International Dividend Stocks Can Produce $19,000 a Year and Reduce U.S. Concentration Risk - Jun 7th, 2026 6:20 am
Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica - Jun 5th, 2026 4:05 pm
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag - Jun 5th, 2026 10:04 am
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years - Jun 4th, 2026 4:15 am
Cosentyx PMR Data Puts Novartis Pipeline And Earnings Story In Focus - Jun 4th, 2026 3:12 am
Purna Pharmaceuticals Names Marc Verbruggen as Managing Director - Jun 4th, 2026 1:02 am
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy - Jun 3rd, 2026 12:00 pm
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients - Jun 3rd, 2026 9:30 am
US Equity Futures Mixed Pre-Bell as US, Iran Continue Military Strikes in Middle East - Jun 3rd, 2026 7:04 am
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - Jun 3rd, 2026 5:57 am
Getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick. - Jun 3rd, 2026 1:30 am
Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial - Jun 2nd, 2026 1:09 pm
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture - Jun 2nd, 2026 9:28 am
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy - Jun 2nd, 2026 9:09 am
Wayleadr Announces Majority Growth Investment to Accelerate Global Expansion - Jun 2nd, 2026 7:00 am
Shell And Total Energize LVHI’s Income Stream As Retirees Seek Stable Foreign Yields - Jun 1st, 2026 9:42 am
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML - Jun 1st, 2026 5:15 am
Novartis announces results on rPFS improvements across subgroups with Pluvicto - May 31st, 2026 11:50 pm
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases - May 31st, 2026 11:15 pm